Chemistry:Anagliptin
From HandWiki
Anagliptin (INN; trade name Suiny) is a pharmaceutical drug for the treatment of type 2 diabetes mellitus. It is approved for use in Japan.[1] It belongs to the class of anti-diabetic drugs known as dipeptidyl peptidase-4 inhibitors or "gliptins".[2]
Research
A systematic review and meta-analysis of anagliptin, published in 2024, found that it is effective in lowering blood glucose in people with type 2 diabetes and that it may lower cholesterol.[3]
References
- ↑ "2012 in review - part I: the year's new drugs & biologics". Drugs of Today 49 (1): 33–68. January 2013. doi:10.1358/dot.2013.49.1.1933991. PMID 23362494. http://thomsonreuters.com/business-unit/science/pdf/ls/years_new_drugs_biologics-2012.pdf.
- ↑ "Discovery and pharmacological characterization of N-[2-({2-[(2S)-2-cyanopyrrolidin-1-yl]-2-oxoethyl}amino)-2-methylpropyl]-2-methylpyrazolo[1,5-a]pyrimidine-6-carboxamide hydrochloride (anagliptin hydrochloride salt) as a potent and selective DPP-IV inhibitor". Bioorganic & Medicinal Chemistry 19 (23): 7221–7. December 2011. doi:10.1016/j.bmc.2011.09.043. PMID 22019046.
- ↑ "Role of anagliptin, a dipeptidyl peptidase-4 inhibitor, in managing type 2 diabetes: A systematic review and meta-analysis". Medicine 103 (28). July 2024. doi:10.1097/MD.0000000000038870. PMID 38996148.
 |  |
